Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy
Our study is the largest to date showing the impact of PPI use on immunotherapy toxicity. PPI use may predispose to more severe toxicities and worse outcomes. PPIs may also reduce immunotherapy efficacy, as reflected by worse overall survival. These findings support the judicious use of PPIs in patients receiving ICIs and call for prospective studies to validate our results.
Authors
- Sean Ngo (ORCID: https://orcid.org/0000-0001-7298-2662)
- Samanthika S. Devalaraju
- Stephen Glombicki
- Nitish Mittal (ORCID: https://orcid.org/0000-0002-4934-3157)
- Shilpa Grover (ORCID: https://orcid.org/0000-0001-6268-6843)
- Anusha Shirwaikar Thomas
- Pauline Funchain (ORCID: https://orcid.org/0000-0002-7568-8626)
- Linfeng Lu (ORCID: https://orcid.org/0000-0002-5703-5007)
- Antonio Pizuorno Machado (ORCID: https://orcid.org/0000-0002-4118-6310)
- Malek Shatila (ORCID: https://orcid.org/0000-0001-8503-7811)
- Christine Catinis
- Elliot Baerman (ORCID: https://orcid.org/0000-0002-3750-7855)
- Yinghong Wang (ORCID: https://orcid.org/0000-0002-5148-6130)
- Hao Chi Zhang (ORCID: https://orcid.org/0000-0003-0330-0167)
- Irene Lee (ORCID: https://orcid.org/0000-0003-0552-7429)
- John A. Thompson
- Abdullah Aleem
- Kei Takigawa
Institutions
- Brigham and Women's Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- Fred Hutch Cancer Center (US)
- Stanford Medicine (US)
- Stanford Cancer Institute
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-06-18
- DOI
- https://doi.org/10.6004/jnccn.2025.7023
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18